Age: 67.0
Sex: U
Vaccine: FLU3, FLU3
Symptoms: No adverse event, Wrong product administered
Clinical narrative: FLUZONE NP was given to a 67-year-old patient instead of FLUZONE HD,with no reported adverse event; Initial information received on 23-Oct-2024 regarding an unsolicited valid  non-serious case received from a pharmacist.  This case involves a 67 years old and unknown gender patient who vaccinated With Influenza Usp Trival A-B Subvirion No Preservative Vaccine [Fluzone] instead of  Influenza Usp Trival A-B High Dose Subvirion Vaccine [Fluzone High Dose],with no reported adverse event   The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.  On an unknown date, the patient received a dose of suspect Influenza Usp Trival A-B Subvirion No Preservative Vaccine Suspension for injection to a 67 year old male patient instead of Influenza Usp Trival A-B High Dose Subvirion Vaccine Suspension for injection in pre-filled syringe(unknown lot number, expiry date, dose, and strength ) via unknown route in unknown administration site with no reported adverse event (wrong product administered)( latency same day) for prophylactic vaccination.  Information on the batch number was requested corresponding to the one at time of event occurrence.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error. ; Reporter's Comments: .   Initial information received on 23-Oct-2024 regarding an unsolicited valid  non-serious case received from a pharmacist.  This case involves a 67 years old and unknown gender patient who experienced fluzone np was given to a 67-year-old patient instead of fluzone hd,with no reported adverse event while receiving vaccines INFLUENZA USP TRIVAL A-B HIGH DOSE SUBVIRION VACCINE [FLUZONE HIGH DOSE] and INFLUENZA USP TRIVAL A-B SUBVIRION NO PRESERVATIVE VACCINE [FLUZONE].     The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.    On an unknown date, the patient received a  dose of suspect INFLUENZA USP TRIVAL A-B HIGH DOSE SUBVIRION VACCINE lot number not reported via unknown route in unknown administration site. On an unknown date, the patient received a  dose of suspect INFLUENZA USP TRIVAL A-B SUBVIRION NO PRESERVATIVE VACCINE lot number not reported via unknown route in unknown administration site.  On an unknown date the patient developed a non-serious fluzone np was given to a 67-year-old patient instead of fluzone hd,with no reported adverse event (wrong product administered) (unknown latency) following the administration of INFLUENZA USP TRIVAL A-B SUBVIRION NO PRESERVATIVE VACCINE and (unknown latency) following the administration of INFLUENZA USP TRIVAL A-B HIGH DOSE SUBVIRION VACCINE.  Action taken with INFLUENZA VACCINE TRIVALENT (FLUZONE) and INFLUENZA VACCINE TRIVALENT (FLUZONE HIGH DOSE) was not applicable.  It was not reported if the patient received a corrective treatment for the event (FLUZONE NP was given to a 67-year-old patient instead of FLUZONE HD,with no reported adverse event).  At time of reporting, the outcome was Unknown for the event fluzone np was given to a 67-year-old patient instead of fluzone hd,with no reported adverse event.     This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.